Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

EndoGlide vs Neusidl for the insertion of donor graft in Descemet's stripping automated endothelial keratoplasty: complications management and clinical outcomes

Poster Details

First Author: F. Luengo Gimeno ARGENTINA

Co Author(s):    F. Arasanz                    

Abstract Details


To evaluate complications and clinical outcomes comparing 2 lenticule insertion methods for Descemet stripping automated endothelial keratoplasty (DSAEK).


Arasanz Laser Vision, Buenos Aires, Argentina.


Prospective randomized single-masked study of 49 eyes that underwent DSAEK for Fuchs endothelial dystrophy (FECD) or pseudophakic bullous keratopathy (PBK) between 2012 and 2015 at a single institution. The Tan Endoglide (EG) was used in 22 eyes and the Neusidl injector (NS) was used in 27 eyes as a delivery method for the donor lenticule. Eyes with anterior segment pathology or previous intraocular surgery (except for uncomplicated cataract surgery) were excluded. The main outcome measures were lenticule pachymetry, BSCVA and endothelial cell loss at 3, 6, and 12 months. Complications including rebubbling rate, graft dislocation and graft failure were recorded.


Mean patient age was 70.6 ± 11.6 years (EG) and 67.0 ± 7.55 years (NS) (P=.19). Mean postoperative BSCVA was 20/30 (EG), 20/40 (NS) and 20/40 in both groups at 6 and 12 months respectively (p=0.4). Endothelial cell loss was 40% (EG), 30% (NS) at 6 months and 44% (EG), 34% (NS) at 12 months (p=.03). Dislocations occurred in 2 (9%) eyes in EG group. Rebubbling was done in 6 (27%) and 2 (7%) eyes in EG and NS groups respectively (P=.012), with 0 primary graft failures in both groups and 1 pupillary block episode in EG group.


The use of the Neusidl injector in DSAEK shows comparable visual results to the Tan EndoGlide and it demonstrates better graft outcomes and lower endothelial cell loss at up to 12 months after surgery. However, further investigation is warranted in order to validate these findings.

Financial Disclosure:


Back to Poster listing